Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2023-11-08 Director's Dealing
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 99% confidence The document text is titled 'KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar' (Form for reporting transactions carried out by persons discharging managerial responsibilities). It details a transaction (Kjøp/Buy) involving an insider ('JONAS EINARSSON', STYRELEDER/Chairman of the Board) of shares in ULTIMOVACS ASA. This type of mandatory disclosure regarding personal share transactions by directors and executives is specifically defined as Director's Dealing (DIRS) in the provided schema. The document is a direct report of the transaction, not an announcement of a report.
2023-11-08 Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document explicitly states it is a "Mandatory notification of trade by primary insider" concerning a transaction by the chair of the board (Jónas Einarsson). This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for this is DIRS.
2023-11-08 English
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
Investor Presentation Classification · 99% confidence The document is explicitly titled "Third Quarter 2023 Results Ultimovacs ASA, November 8, 2023" and contains detailed clinical updates, pipeline progress, and financial update sections, characteristic of a quarterly report presentation. The content focuses on clinical trial data (NIPU, INITIUM, FOCUS) and operational milestones achieved during Q3 2023. Although it is a presentation format, its primary purpose is to convey the comprehensive results for the specified interim period. This aligns best with the definition of an Interim / Quarterly Report (IR), rather than just an Earnings Release (ER) which is typically just the highlights, or a Report Publication Announcement (RPA) which only announces the release of a report. Given the depth of clinical and operational data for the quarter, IR is the most appropriate classification.
2023-11-08 English
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 Third Quarter Report' for Ultimovacs ASA. It contains comprehensive financial statements (unaudited), management's discussion and analysis, operational reviews, and clinical trial updates for the third quarter of 2023. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2023
2023-11-08 English
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
Earnings Release Classification · 100% confidence The document explicitly states in the title and opening paragraph that it reports the 'Third Quarter 2023 Financial Results' and provides a 'General Business Update'. It details clinical trial progress, IP updates, and financial figures (operating expenses, cash flow) for Q3 2023. This content structure aligns perfectly with a comprehensive periodic financial report for a period shorter than a year, which corresponds to the Interim / Quarterly Report (IR) definition. Although it mentions the quarterly report and presentation will be published later, the body of the text contains the actual results and updates, making it the report itself, not just an announcement of the report (RPA). The length (9560 chars) also supports it being the full content rather than a brief RPA. Q3 2023
2023-11-08 English
Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation'. It explicitly invites stakeholders to a webcast presentation for the third quarter 2023 results and states that 'The report and presentation will be available on the company website from 08:00 CET the same day.' Since the document is very short (1250 chars) and its primary function is to announce the timing and access method for the upcoming release of the Q3 results report and presentation, it fits the definition of a Report Publication Announcement (RPA). It is not the actual Earnings Release (ER) or Interim Report (IR) itself.
2023-11-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.